SCHEMBL6583709

SCHEMBL6583709

COc1cc2c(cc1Cl)C(c1ccccc1Cl)(N1Cc3ccccc3C[C@H]1C(=O)N(C)C)C(=O)N2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
OXTR P30559 3/20 0.34
AVPR1A P37288 3/20 0.34
AVPR1B P47901 3/20 0.34
AVPR2 P30518 2/20 0.34
GPR65 Q8IYL9 1/20 0.34
AKR1B1 P15121 1/20 0.34
MAPT P10636 5/20 0.34
ACHE P22303 1/20 0.33
HPGD P15428 2/20 0.33
HTT P42858 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 2/20 0.32
CHEK1 O14757 1/20 0.32
JAK2 O60674 1/20 0.32
ALOX15 P16050 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6579744 0.91 GHSR (0.33) POLBMDM2
SCHEMBL6582612 0.91 OXTR (0.39) POLBMEN1KMT2AOXTRAVPR1A
SCHEMBL6582733 0.89 AVPR2 (0.38) POLBMEN1KMT2AOXTRAVPR1A
SCHEMBL6584708 0.86 AKR1C3 (0.41) POLBMEN1KMT2AOXTRAVPR1A
SCHEMBL2502274 0.85 AVPR1A (0.45) POLBMEN1KMT2AOXTRAVPR1A
SCHEMBL4590303 0.84 OXTR (0.43) POLBOXTRAVPR1AAVPR1BAVPR2
SCHEMBL5355344 0.83 AVPR1A (0.42) OXTRAVPR1AAVPR1BAVPR2GPR65
SCHEMBL6585299 0.82 OXTR (0.40) POLBMEN1KMT2AOXTRAVPR1A
SCHEMBL6581793 0.80 AVPR1B (0.46) POLBMEN1KMT2AOXTRAVPR1A
SCHEMBL6949558 0.79 OXTR (0.44) OXTRAVPR1AAVPR1BAVPR2GPR65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1259505-B1 NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI SYNTHELABO (FR) 2004-05-19 EP disclosed
US-6596732-B2 Their solvates and/or hydrates exhibiting an affinity and a selectivity for arginine-vasopressin V1b receptors or for both V1b and V1a receptors. hormone known for its antidiuretic effect and its effect in regulating arterial pressure. SANOFI-SYNTHELABO (FR) 2003-07-22 US disclosed
US-20030109545-A1 Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2003-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109545-A1 Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same AVPR2, AVPR1B, AVPR1A POLB 4365/4885MEN1 626/4885KMT2A 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.